$CAPR In 2015 and 2016 Sarepta was trading in the $30s and $40s while waiting for the FDAs decision on their DMD drug eteplirsin for approval. On April 26, 2016 the FDA denied Sarepta and the stock tanked to $8.06. CAPR should mirror Sareptas price range prior to FDAs decision. The difference between the drug companies, CAPR had stellar clinical PH2 results, Sareptas was questionable and was not approved initially by the FDA.
  • 23